Daewoong Pharmaceutical (Co-CEOs Seongsoo Park and Chang-Jae Lee), a leading healthcare company in Korea, announced the official launch of its high-purity, high-quality botulinum toxin product, NABOTA ...

This article provides an updated list of the Dividend Kings in 2025, select financial data and analysis. The list and data ...

AbbVie's growth thrives on strong earnings, a robust immunology portfolio, and diversification. See why ABBV stock is a ...

Johnson & Johnson may outshine AbbVie as a top defensive stock pick. Read how Ben Graham's framework evaluates each ...

AbbVie is using innovative technologies like AI, wearables and automation to speed up drug discovery, clinical trials, and ...

AbbVie forecasts 7% growth in 2025 and 10-11% in 2026-2027 for its immunology segment. Goldman Sachs raises AbbVie’s price target to $208, citing Skyrizi and Rinvoq as key growth drivers. Get ...

NORTH CHICAGO, Ill. and SAN DIEGO, Jan. 23, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and Neomorph, Inc. today announced a collaboration and option-to-license agreement to develop novel molecular ...

AbbVie's Rinvoq and Skyrizi could eventually surpass Humira's peak sales. The dividend is well-funded, though an expensive acquisition spree may lead to slower growth. The stock's solid growth ...

Ten months after Pfizer scored approval in Europe for Emblaveo (aztreonam and avibactam) to treat complicated intra-abdominal infections (cIAIs), AbbVie has done the same in the U.S., ...

AbbVie and Neomorph are forming a partnership and option-to-license agreement to develop molecular glue degraders, aiming to introduce a new class of treatments across oncology and immunology.

AbbVie reported better-than-expected fourth-quarter earnings. Strong demand for the company's Skyrizi and Rinvoq autoimmune therapeutics has helped offset the decline in Humira sales since losing ...